VTE Diagnosis: What's New?

Dr. Aurélien Delluc highlights key advancements in Venous Thromboembolism (VTE) diagnosis from the ISTH 2026 Congress. 

Cancer-Associated Thrombosis & Hemostasis

Dr. Darko Antic presents key insights into the complex management of cancer-associated thrombosis (CAT) and hemostasis at the ISTH 2026 Congress. This brief highlights the latest clinical evidence on anticoagulation strategies, balancing bleeding versus recurrent thrombotic risks, and customizing treatment pathways for oncological patients.

Introductions to the ISTH Guidelines and Guidance Documents - report from ISTH 2026

Dr. Fionnuala Ní Áinle presents an essential overview of the latest ISTH Guidelines and Guidance Documents at the ISTH 2026 Congress. This brief highlights key clinical recommendations, the methodological rigor behind the guidelines, and practical implementation strategies to standardize care in thrombosis and hemostasis globally.

Acute and Long-Term Management of Severe DVT by ESVM VTE Guideline

Dr. Oliver Schlager outlines the acute and long-term management of severe deep vein thrombosis (DVT) in alignment with the ESVM VTE Guidelines at the ISTH 2026 Congress. This brief highlights key recommendations for early intervention, tailored anticoagulation duration, and strategies to minimize the risk of post-thrombotic syndrome (PTS).

Anticoagulant Associated Bleeding: Specific Populations and Reversal

Dr. Kerstin de Wit highlights critical updates on anticoagulant-associated bleeding risks, management, and reversal strategies presented at the ISTH 2026 Congress, featuring the following key studies: - Perioperative Anticoagulation Management and Outcomes in Thrombotic Antiphospholipid Syndrome: A Single-Center Cohort Study – Miguel Paquette (Ottawa, Canada) - The Incidence and Outcomes of LMWH-Related ISTH defined Major Bleeding: A National Observational Cohort Study – Gwendoline Fuller (London, UK) - Validation of a Treatment Decision Pathway for Andexanet Alfa (VALIDA) – Jan Beyer-Westendorf (Dresden, Germany) - Reversal efficacy of novel single domain antibodies against rivaroxaban, edoxaban or apixaban in vitro and ex vivo: studying platelet-dependent clot formation under flow – Xiang Gui (Maastricht, The Netherlands)

Future Anticoagulants

Dr. Marco Donadini highlights the next generation of antithrombotic therapies at the ISTH 2026 Congress, featuring these breakthrough presentations: - A Synthetic, Allosteric, Highly Selective, Reversible Inhibitor of Human Factor XIa for Venous and Lung (Cancer-Associated) Thrombosis – Umesh Desai (Richmond, US) - EXocite ACTive site (EXACT) Inhibitors as Potent RNA Aptamer-Based Anticoagulants Targeting Various Coagulation Factors – Jeffrey Clancy (Durham, US) - Efficacy-Safety Paradox of Next-Gen Factor XI/XIa Inhibitors: Meta-Analysis of Phase 2 and 3 Trials – Rahul Falodia (Jodhpur, India) - BAY 3389934: A Dual Factor IIa/Xa Inhibitor – Nicole Juffermans (Rotterdam, The Netherlands) - REGN9533, a monoclonal antibody targeting Factor XII (FXII), Phase 1 study – Frédéric Vanhoutte (Antwerp, Belgium)

Updated recommendations on the diagnosis and classification of FXIII deficiencies / ISTH 2026 Diagnostic Highlights

Dr. Zsuzsanna Bagoly presents the highly anticipated updated clinical recommendations for the diagnosis and classification of Factor XIII (FXIII) deficiencies at the ISTH 2026 Congress. This essential brief outlines the revised diagnostic algorithms, standardized laboratory assays, and clear classification pathways designed to improve the detection and management of this underdiagnosed, life-threatening bleeding disorder.

Highlights of ISTH Guidelines and Guidance Documents

Dr. James Douketis delivers an essential overview of the key highlights from the newly updated ISTH guidelines and guidance documents at the ISTH 2026 Congress. This targeted brief focuses on practical, evidence-based clinical recommendations, highlighting two major clinical updates: Surgical and Procedural Bleed Risk Stratification for Anticoagulated Patients Undergoing Planned Surgery – A refined, three-tier classification framework to optimize periprocedural anticoagulation management. Monitoring and Management of Therapeutic-dose UFH in Practice – Key updates on standardizing and improving the safety of therapeutic unfractionated heparin (UFH) dosing and monitoring.